Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 3, 2003, Pages 311-316

  Bettinardi, Nora ^a   Felicetta, Irene ^b   Tomasi, Paolo A ^c   Colombo, Carla ^d  

^a Ospedale Sesto San Giovanni   (Italy)

^b ICP   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

CA 19 9; Cystic fibrosis; Liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; ISOENZYME; LIVER ENZYME;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ENZYME ANALYSIS; FEMALE; HUMAN; LIVER DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; AMYLASES; BILE ACIDS AND SALTS; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INFANT; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; PROGNOSIS; ROC CURVE;

EID: 0037260297     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.050     Document Type: Article

References (22)

1. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85:350-5.
2. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108:865-9.
3. Dietel M, Arps H, Klapdor R, Muller-Hagen S, Sieck M, Hoffmann L. Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue. J Cancer Res Clin Oncol 1986; 111:257-65.
4. Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on tumor markers CA 19-9 and CEA. Ann Clin Biochem 1998; 35:99-103.
5. Halme L, Karkkainen P, Isoniemi H, Makisalo H, von Bogulawski K, Hockerstedt K. Carbohydrate 19-9 antigen as a marker of non-malignant hepatocytic ductular transformation in patients with acute liver failure. Scand J Gastroenterol 1999;34:426-31.
6. Collazos J, Genolla J, Ruibal A. CA 19-9 in non-neoplastic liver disease. A clinical and laboratory study. Clin Chim Acta 1992; 210:145-51.
7. Kinnman N, Lindblad A, Housset C Buentke E, Scheynius A, Stran Hultcrantz R. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Hepatology 2000; 32:334-40.
8. Cohn JA, String TV, Picciotto ME, Nairn AC, Collins FS, Fitz JG. Localization of cystic fibrosis transmembrane conduttance regulator in human bile duct epithelial cells. Gastroenterology 1993; 105:1857-64.
9. Colombo C, Battezzati PM, Strazzabosco M, Podda M. Liver and biliary problems in cystic fibrosis. Semin Liver Dis 1998; 18:227-35.
10. Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors and outcome. Hepatology 2002; 36:1374-82.
11. Narkewicz MR. Markers of cystic fibrosis - associated liver disease. J Pediatr Gastroenterol Nutr 2001; 32:421-2.
12. Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui LC, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992; 50:1178-84.
13. National Committee for Clinical Laboratory Standards. GP10-P proposed guideline. Villanova, Pennsylvania. National Committee for Clinical Laboratory Standards, 1985; 143-69.
14. 7. Gaskin KJ, Waters DLM, Howman-Giles R, De Silva M, Earl JW, Martin HCO, et al. Liver disease and common bile-duct stenosis in cystic fibrosis. N Eng J Med 1988; 318:340-6.
15. Sohda T, Iwata Y, Shijo H, Egashira Y, Egashira K, Okunura M, Increased expression of proliferating cell nuclear antigen in autoimmune hepatitis in a patient with raised serum concentration of CA 19-9. J Clin Pathol 1998; 51:167-73.
16. von Ritter C, Eder MI, Stieber P, Lamerz R, Jungst D, Strigl M, et al. Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9. Anti-cancer Res 1997; 17:2931-4.
17. Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers 2000; 15: 226-30.
18. Gupta MK, Arciaga R, Bocci L. Measurement of a monoclonal antibody defined antigen (CA 19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen. Cancer 1985; 56:277-83.
19. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumor marker CA 19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000; 5:474-9.
20. Augarten A, Aviram M, Yahav Y, Szeinberg A, Rivlin J, Ben Tur L, et al. Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with normal or borderline sweat test. [abstract]. Ped Pulmonol 2000; (22 Suppl): 214S.
21. Frates RC, Kaizu T, Last JA. Mucus Glycoproteins secreted by respiratory epithelial tissue from cystic fibrosis patients. Pediatr Res 1983; 17:30-4.
22. Leigh MW. Airway secretions. In: Yankaskas JR, Knowles MR, editors. Cystic fibrosis in adults. Philadelphia: Lippincott-Raven Publ., 1999:69-92.